Liqiang Wei

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Clinical features, central nervous system risk, and therapeutic outcomes in primary sinonasal diffuse large B-cell lymphoma: a retrospective cohort study of 94 patients.

Clinical features, central nervous system risk, and therapeutic outcomes in primary sinonasal diffuse large B-cell lymphoma: a retrospective cohort study of 94 patients.

Journal: Translational cancer research

Published: January 12, 2026

Analysis of the treatment and prognosis of 266 cases of extranodal natural killer/T-cell lymphoma, nasal type in a single medical center.

Analysis of the treatment and prognosis of 266 cases of extranodal natural killer/T-cell lymphoma, nasal type in a single medical center.

Journal: Frontiers in oncology

Published: February 20, 2024

Toxic epidermal necrosis caused by programmed cell death protein 1 inhibitors in a patient receiving chimeric antigen receptor-T cell therapy.

Toxic epidermal necrosis caused by programmed cell death protein 1 inhibitors in a patient receiving chimeric antigen receptor-T cell therapy.

Journal: Chinese medical journal

Published: April 07, 2023

Combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in treatment of advanced extranodal NK/T-cell lymphoma.

Combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in treatment of advanced extranodal NK/T-cell lymphoma.

Journal: Chinese medical journal

Published: March 20, 2023

Integrating reproductive states and social cues in the control of sociosexual behaviors.

Integrating reproductive states and social cues in the control of sociosexual behaviors.

Journal: Cell

Published: March 10, 2023

Dose-adjusted EPOCH-R vs. R-CHOP in frontline management of Waldeyer's ring diffuse large B-cell lymphoma: a retrospective study from a single institution.

Dose-adjusted EPOCH-R vs. R-CHOP in frontline management of Waldeyer's ring diffuse large B-cell lymphoma: a retrospective study from a single institution.

Journal: Chinese medical journal

Published: February 13, 2023

A novel prognostic model based on ferritin and nomogram-revised risk index could better stratify patients with extranodal natural killer/T-cell lymphoma.

A novel prognostic model based on ferritin and nomogram-revised risk index could better stratify patients with extranodal natural killer/T-cell lymphoma.

Journal: Cancer medicine

Published: August 06, 2022

A common thalamic hub for general and defensive arousal control.

A common thalamic hub for general and defensive arousal control.

Journal: Neuron

Published: March 11, 2022

CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase.

CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase.

Journal: Frontiers in immunology

Published: December 05, 2021

Corrigendum to "SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type" [Leukemia Res. 96 (2020) 106422].

Corrigendum to "SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type" [Leukemia Res. 96 (2020) 106422].

Journal: Leukemia research

Published: September 28, 2020

Treatment outcomes and prognostic analysis of elderly patients with extranodal natural killer/T-cell lymphoma, nasal type: a retrospective analysis.

Treatment outcomes and prognostic analysis of elderly patients with extranodal natural killer/T-cell lymphoma, nasal type: a retrospective analysis.

Journal: Leukemia & lymphoma

Published: July 21, 2020

Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.

Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.

Journal: Journal of cancer research and clinical oncology

Published: May 29, 2020

Showing 1-12 of 16

Last Updated: 09/26/2026